AbbVie will pay $40 million upfront for a strategic collaboration and option-to-license agreement with DISCO Pharmaceuticals, a German biotech working on a class of cancer drugs called AND-gated bispecifics. The deal includes up to $2.5 billion in option, development, and other milestones, for a total potential value of about $2.54 billion, Reuters reported, plus tiered royalties on worldwide sales.

The structure tells you what stage the science is at. DISCO will run specified research, and AbbVie will have the right to exercise options to exclusively license selected programs. The number of programs and the targets have not been disclosed. The collaboration is early, and the payments are contingent on the work that follows.

What AND-gated means

A bispecific antibody is engineered to bind two different targets at once. In oncology, the idea is often to bring a T cell close to a tumor cell by binding a T-cell receptor on one side and a tumor antigen on the other. The approach has produced approved drugs, and it has also produced a familiar problem: if the tumor target is present on healthy tissue, the drug can attack the healthy tissue too.

AND-gated bispecifics try to solve that problem with a conditional design. The antibody binds strongly only when two distinct antigens are present on the same cell. A cell that carries one of the antigens but not the other does not trigger the same response. The logic is a biological AND gate: both inputs have to be true for the output to fire.

The appeal is selectivity. Many tumor antigens are not truly tumor-specific; they are overexpressed on cancer cells and present at lower levels on normal cells. Requiring a pair of antigens narrows the set of cells that meet the condition. The hope is that the drug can hit the tumor hard while leaving healthy tissue alone, which would address the on-target, off-tumor toxicity that has limited the field.

Bispecifics have another safety issue that the AND-gate design does not directly solve. T-cell-engaging bispecifics can trigger cytokine release syndrome, an immune reaction that ranges from fever to a serious systemic response. The risk depends on how strongly the drug activates T cells and where that activation happens. A more selective target pair may reduce the risk by keeping the activation at the tumor, but the immune reaction is a property of the drug class, and the early trials will be watched for it.

The platform

DISCO's platform is called DISCOtech. It maps the surface of cancer cells, a field the company calls the surfaceome, to identify pairs of targets that appear together on tumor cells and rarely together on healthy cells. The company then designs bispecific antibodies against those pairs.

The surfaceome is the set of proteins exposed on the outside of a cell. It is large and varies by tissue and by disease, which is what makes it a useful map for drug developers. A target that is present on a tumor cell but rare on healthy cells is a candidate. A pair of targets that appear together on the tumor and rarely together elsewhere is a better candidate, because the drug needs both inputs to fire.

The platform is the product in a deal like this. AbbVie is not buying a single drug with a known clinical profile. It is buying access to a discovery engine and an option on what the engine produces. That is why the upfront payment is modest relative to the milestones, and why the milestones are where most of the value sits. An option-to-license deal lets the buyer pay for information as it accumulates: the upfront buys the collaboration, and the later payments are tied to programs that clear specific scientific hurdles.

DISCO's lead programs are in small cell lung cancer and microsatellite-stable colorectal cancer. Both are solid tumors with high unmet need and limited treatment options. The company's chief executive, Mark Manfredi, has said a development candidate is expected in the second half of next year.

The structure of the deal

The agreement gives AbbVie options rather than assets. DISCO runs the specified research, and AbbVie can choose which programs to license exclusively. The upfront payment buys the collaboration and the right to look. The milestones are paid as programs advance, and the royalties are paid if a product reaches the market. That uncertainty is part of the reason the upfront payment is modest.

That structure shares the risk. AbbVie does not carry the full cost of early discovery, and DISCO gets a partner with the resources to develop what it finds. The tradeoff is that DISCO gives up a large share of the eventual value, and AbbVie takes on the risk that the platform does not produce a viable candidate.

Deals like this have become the standard way for large pharma to access early discovery. A full acquisition of a preclinical company is expensive and risky, and it commits the buyer before the science is proven. An option deal lets the buyer pay for access, watch the research, and decide later. The seller gets capital and a validation signal without giving up the whole company.

The deal is also a signal about AbbVie's oncology strategy. The company has been rebuilding its pipeline as its immunology franchise matures, and it has been active in licensing. In January, it paid RemeGen $650 million upfront for ex-China rights to a solid-tumor bispecific. The DISCO deal adds a discovery platform to that portfolio.

The venture connection

AbbVie Ventures was an investor in DISCO's €36 million seed round in December 2025. That relationship gave AbbVie an early look at the platform, and it is a common path for a large company to move from investor to partner.

The connection also shapes the deal's economics. An existing investor has more information than a new buyer, and the upfront payment reflects that. The option structure lets AbbVie continue to learn before committing the larger sums.

Cologne has become a small hub for this kind of biotech. DISCO's seed round, led with venture money and backed by AbbVie's venture arm, gave it the runway to build the platform before the pharma deals arrived. The German research base and the proximity to European talent are part of the story, and so is the willingness of U.S. pharma to look outside its own backyard for early science.

DISCO has now signed two major pharma collaborations in a year. The first was with Amgen in January, worth up to $618 million. The second is the AbbVie deal, which is larger and broader. The pattern suggests the platform has convinced more than one partner that its target-pair approach is worth funding.

The competitive field

Bispecifics are one of the most active areas in oncology. The approved drugs have shown that the approach can work, and the next generation is focused on reducing toxicity and expanding the set of targets. Companies are experimenting with conditional designs, masked antibodies, and target pairs, all with the same goal: a wider therapeutic window.

The AND-gate design is one version of that idea. Its advantage is conceptual clarity: two antigens, one condition. Its challenge is biological complexity. The pair has to be present on the tumor, absent enough on healthy tissue, and accessible to the antibody. The platform's ability to find such pairs is the whole bet.

The competition for target pairs is global. U.S., European, and Chinese biotechs are all working on conditional bispecifics, and the large pharma companies are licensing the most promising platforms. The winners will be the teams that can show a clean safety profile and a durable response in early trials. A platform that finds good pairs but cannot manufacture or develop them will not capture the value.

Small cell lung cancer and MSS colorectal cancer are sensible first tests. Both have few effective options and a high unmet need, which can justify an accelerated development path. They are also diseases where a targeted agent with a clean safety profile would be valuable.

What early stage means for patients

The regulatory path from a development candidate to an approved drug is long. A company has to complete preclinical safety work, file an investigational new drug application, run Phase 1 trials for safety and dosing, and then expand into efficacy trials. For a novel bispecific, regulators will want a clear picture of the target pair, the immune activation, and the risk of cytokine release. The timeline is measured in years, and the company has not disclosed a filing date for the first program.

Nothing in this deal changes care today. The programs are preclinical, the targets are undisclosed, and the first development candidate is expected in the second half of next year. A patient should not read the announcement as a treatment that is about to arrive.

The deal does show where the industry thinks the next wave of cancer drugs will come from. The first bispecifics proved the concept. The next generation is trying to make the concept safer and more precise. The companies that find the right target pairs will have a valuable asset, and the companies that fund them will have a stake in the outcome.

The bet on pairs

The AbbVie deal is a bet that DISCO's platform can find target pairs that are selective enough to matter and accessible enough to drug. The $40 million upfront is the price of that bet. The $2.5 billion in milestones is what the bet is worth if it works.

For DISCO, the deal is validation and capital. For AbbVie, it is an option on a platform at a stage when the science is promising and unproven. For patients, it is a reason to watch the field, not a reason to change a treatment plan. The next milestone is the development candidate, and the next few years will show whether the AND gate is a real advance or a clever idea that does not translate. The deal's size is a statement of hope, not a result. The first human data will be the test that matters, and it is years away.

Primary sources

  1. FierceBiotech, for the deal terms, the AND-gated design, and the DISCOtech platform.
  2. Reuters via the Sacramento Bee, for the total potential deal value and the option structure.
  3. DISCO Pharmaceuticals' announcement, for the company's description of the platform and its lead programs.